Global Medical Cannabis Imports Surge as Germany Sets New Record

Germany Posts Record Monthly Import Volume

Germany imported a record volume of medical cannabis in August 2026, extending its position as the world's largest legal cannabis import market. The country's Federal Institute for Drugs and Medical Devices (BfArM) reported imports exceeded 12,000 kilograms for the month, up 18 percent from July and surpassing the previous high set in March.

German pharmacies dispensed approximately 9,800 kg to patients during the same period. The gap? Inventory build-ahead of anticipated Q4 demand and new patient onboarding following April's partial legalization of adult-use possession.

European Suppliers Capture Market Share

Netherlands-based cultivators supplied 41 percent of Germany's August imports, followed by Portugal at 23 percent and Israel at 19 percent. Canadian producers, which dominated German imports through 2024, accounted for just 11 percent of August volume.

The shift reflects tightening EU Good Manufacturing Practice (GMP) enforcement and logistics advantages for intra-EU shipments. Transport times from Dutch and Portuguese facilities average 48 hours. Canadian exporters need 7-10 days.

Israel Expands Export Footprint

Israeli medical cannabis exports reached $47 million in the first eight months of 2026, already exceeding full-year 2025 totals. The Israel Medical Cannabis Agency (IMCA) reported shipments to 15 countries, with Germany, Australia, and the United Kingdom comprising 74 percent of export value.

Israel authorized eight additional cultivators for export in June. That brings the licensed exporter pool to 23 facilities. Approved cultivation canopy for export-destined product now exceeds 185,000 square meters.

Australia Sees Import Decline Amid Domestic Ramp

Australian medical cannabis imports fell 29 percent year-over-year in Q2 2026 as domestic production scaled. The Therapeutic Goods Administration (TGA) reported 2,890 kg imported during the quarter, down from 4,070 kg in Q2 2025.

Local cultivation supplied 68 percent of the 14,200 kg dispensed to Australian patients in Q2. The country's 89 licensed cultivators produced 9,650 kg domestically during the period.

UK Prescription Volume Climbs

UK medical cannabis prescriptions increased 34 percent in the 12 months ending August 2026. The National Health Service and private clinics issued approximately 89,000 prescriptions during the period, according to data compiled by the Centre for Medicinal Cannabis.

Flower products accounted for 61 percent of prescriptions, with oil formulations comprising most of the remainder. Average monthly prescription cost declined to £195 from £240 a year earlier as competition among private clinics intensified.

Trade Flow Implications for North American Exporters

The data underscores margin pressure on Canadian licensed producers reliant on export revenue. Tilray Brands (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB) derived 12-18 percent of Q2 2026 revenue from international medical sales, down from 22-31 percent in Q2 2025.

Analysts at Stifel downgraded the three stocks in August, citing European supply-chain localization and Australian import substitution as structural headwinds. The firms' combined international medical revenue is forecast to decline 15 percent in fiscal 2027.

What Comes Next

Germany's October import data will signal whether August's record reflects sustained demand or temporary inventory stocking. Israel's export growth depends on securing additional country approvals; applications are pending in France, Italy, and Poland. For full background on this story, see the CannIntel topic hub on Global Medical Cannabis Trade.